Scope
The multisociety recommendations address the short-term benefits and risks of corticosteroid injections in joints and musculoskeletal soft tissue. Selection depends on the condition and site; lower effective doses, suitable guidance, infection control and anticipation of systemic effects are central to safe practice.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Choose the indication, preparation and guidance
- Joint corticosteroid injections may be used for short-term relief of symptomatic inflammatory or degenerative arthritis. There is insufficient evidence to recommend one intra-articular corticosteroid preparation over another. [1]
- Image guidance may be preferred to improve placement accuracy, especially in morbid obesity. Ultrasound improves accuracy over landmark techniques; the summary does not establish a general accuracy advantage over fluoroscopy. [1]
- Do not inject through infected skin, into suspected infectious arthritis or a fracture site, in suspected bacteraemia, or after hypersensitivity to previous injectable corticosteroid. These are listed as absolute contraindications. [1]
- Consider relative contraindications including previous lack of efficacy, severe immunocompromise, coagulopathy, a joint prosthesis and poorly controlled diabetes. [1]
Use shoulder and elbow injections selectively
- For an initial shoulder injection, use no more than the equivalent of triamcinolone or methylprednisolone 20 mg. Offer injection for short-term relief of moderate-to-severe pain and disability when appropriate conservative options are unavailable or unsuccessful. [1]
- Offer physiotherapy or home exercises alongside shoulder injection. The benefit of injection should be discussed as short term rather than a promise of durable cure. [1]
- For peritendinous injection of the long head of biceps, ultrasound is recommended over a landmark approach. Fluoroscopy is also recommended over landmarks, with ultrasound offering higher placement accuracy than fluoroscopy in the cited evidence. [1]
- An injection may be considered for short-term lateral epicondylosis pain if not contraindicated; long-term superiority over conservative care or physiotherapy is not established. Aspiration followed by corticosteroid may be offered for non-septic olecranon bursitis. [1]
Use the lowest effective dose and assess structural risk
- Before intra-articular hip injection, obtain screening radiography to verify baseline pathology, including osteonecrosis. Use caution with high doses or multiple injections; consider the lowest effective dose and a longer interval between repeats. [1]
- For hip injection, consider triamcinolone 40 mg or an equivalent corticosteroid dose. Discuss potential structural adverse effects, including cartilage loss, insufficiency fracture, osteonecrosis and, rarely, rapid joint destruction. [1]
- For greater trochanter pain syndrome, offer education and home physiotherapy before or alongside injection. Trochanteric bursa injection may be performed using landmarks. [1]
- For knee osteoarthritis, use the lowest effective corticosteroid dose and extend repeat intervals when possible. The recommended initial maximum is triamcinolone acetonide 40 mg or an equivalent particulate corticosteroid. [1]
- Explain that repeated intra-articular corticosteroid treatment is associated with small-volume cartilage loss, with greater likelihood or magnitude at higher doses or over longer treatment duration. [1]
Select hand, wrist and heel procedures by diagnosis
- Prefer ultrasound guidance for small joints of the wrists, hands, feet and ankles. In active rheumatoid arthritis of wrist or hand joints, injection may be used as an adjunct for pain, function and inflammatory symptoms. [1]
- For trigger finger, use triamcinolone or methylprednisolone equivalent to 20 mg rather than 5 or 10 mg. For De Quervain tenosynovitis, offer a thumb splint alongside injection. [1]
- Corticosteroid injection may be used for rheumatic inflammatory heel pain that has not responded to conservative measures. Avoid plantar-fascia corticosteroid injection for non-inflammatory plantar heel pain. [1]
Plan monitoring and coordinate with surgery
- Advise people with diabetes to monitor glucose carefully for at least 48 hours after injection and until it returns to normal, potentially up to 7 days. Significant hyperglycaemia may occur and the peak can be delayed. [1]
- Do not routinely measure cortisol before or after injection. In a compatible clinical setting, consider adrenal crisis when hypotension develops in the days or weeks after an intra-articular corticosteroid injection. [1]
- For chronic stable warfarin therapy with good control and no bleeding symptoms, warfarin need not be withheld for intra-articular injection; the patient may remain within the therapeutic INR range. [1]
- Use strict aseptic technique and standard infection-control practices for intra-articular corticosteroid injections. [1]
- Avoid injection into a joint scheduled for replacement within 3 months, particularly within 1 month. If considering an injection within that preoperative period, discuss risks and benefits with the surgeon. [1]
Limitations and use
- This covers the society-partner recommendation summary rather than the full article and external dose tables. It does not establish a universal repeat-injection interval or complete corticosteroid-equivalence table. Anticoagulation advice here is specific to the stated stable-warfarin population and must not be extrapolated to every antithrombotic regimen.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Use and safety of corticosteroid injections in joints and musculoskeletal soft tissue — focused recommendation source
Selected recommendation material consulted
Publication details
- Issuing organisation
- ASRA / AAPM / ASIPP / IPSIS
- First published
- 26 February 2025
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.